Adamas Pharma receives $40 mn milestone payment from Forest Labs for MDX-8704

Adamas Pharmaceuticals, Inc., a company dedicated to improving the lives of those affected by CNS disorders, has received $40 million in milestone payments from Forest Laboratories Holdings Limited for MDX-8704. MDX-8704 is a fixed dosed combination (FDC) of Namenda XR (memantine HCl extended release capsules) and donepezil HCl being developed as a once daily therapy for the treatment of moderate-to-severe dementia of the Alzheimer€™s type in the United States.

Read the source article at pharmabiz.com

About the Author

Leave a Reply